## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

## **Equality impact assessment – Scoping**

## STA Crisaborole for treating mild to moderate atopic dermatitis in people aged 2 years and older

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During consultation it was raised that the assessment scales for the severity of atopic dermatitis may underestimate disease severity in people from some skin colours. Skin colour has been included as a subgroup in the scope.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

It is possible that the assessment tools for assessing the severity of atopic dermatitis and the response to treatment may not be sensitive enough in people with some skin colours. This should be explored with the clinical experts at the committee meeting.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Skin colour has been added as a subgroup.

Issue date: July 2019

4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
Not applicable.	
pprov	red by Associate Director (name):Nicole Elliott

Date: 11/07/2019

Issue date: July 2019 2 of 2